Co-encapsulated nanoparticles of Erlotinib and Quercetin for targeting lung cancer through nuclear EGFR and PI3K/AKT inhibition
Parimala Devi Ganthala, Sateesh Alavala, Naveen Chella, Sai Balaji Andugulapati, Nagendra Babu Bathini, Ramakrishna Sistla
Topics & Concepts
ErlotinibPharmacologyChemistryIn vivoEpidermal growth factor receptorPI3K/AKT/mTOR pathwayLung cancerApoptosisCancer researchMedicineOncologyBiochemistryReceptorBiologyBiotechnologyLung Cancer Treatments and MutationsCancer, Lipids, and MetabolismLung Cancer Research Studies